RhoVac reports patient recruitment for phase I/II study is now complete
3 July, 2017
RhoVac AB (“RhoVac”) announced today, July 3 2017, that a total of 22 patients were recruited for company’s clinical I/II study. Patient recruitment for this phase of study is not terminated.
RhoVac’s phase I/II clinical trial started in early 2017 and first patient was dosed in April. The study focuses on patients with diagnosed prostate cancer in control phase. The primary objective of the study is to evaluate the safety of RV001 vaccine therapy and the secondary goal is to evaluate the immune response in treatment with the cancer vaccine RV001.
As proposed in the clinical trial protocol, the Rhovac can recruit a maximum of 25 patients for the clinical study; the target has been to recruit minimum 20 patients. All patients had to undergo a screening to ensure compliance with all inclusion and exclusion criteria required in the protocol. A total of 22 patients completed the screening and are now approved for phase I/II clinical trial. The patient recruitment phase of the study is therefore terminated. The study continues with the treatment phase and the completion and reporting is due for Q2 2018.
Comments from Principal Investigator Jesper Sonne, MD, DMedSc
“There has been a great interest in this simple vaccine treatment. If we can show that this cancer vaccine can stimulate a relevant immune response against metastasis, the next step would be a major experiment in which the effect of the vaccine on metastasis will be studied.”
Comments from RhoVac’s CEO, Anders Ljungqvist
“It is a remarkable achievement for RhoVac that we have been able to recruit the proposed number of patients for company’s clinical phase I/II study in approximately three months; a fantastic result in a time when patient recruitment for clinical trials is challenging. I would like to thank the Copenhagen Prostate Cancer Center at Rigshospitalet, the phase-I unit Zelo at Bispebjerg and Frederiksberg Hospital plus DanTrials ApS for a highly professional and dedicated recruitment work. There has been an outstanding collaboration. The treatment phase in the clinical study is now proceeding as planned.”
For more information, please contact:
Anders Ljungqvist – CEO, RhoVac AB
Phone: +45 4083 2365
This is an English version of an original Swedish press release communicated by RhoVac AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that RhoVac AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 3 July 2017.
About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company’s main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac’s first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on Spotlight Stock Market, Sweden, a Multilateral Trading Facility (MTF), since March 2016 and has approximately 1,700 shareholders. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com.